Title : Understanding MOGAD starts here: Rare disease awareness for patients and families
Abstract:
Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) is a rare, neurological autoimmune disease that affects the central nervous system. It targets myelin oligodendrocyte glycoprotein (MOG), a protein that is expressed on the outer surface of the myelin sheath, leaving patients experiencing multiple manifestations of neurological issues. Despite its distinct pathophysiology and treatment implications compared to Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder, accessible and patient centered resources for MOGAD have been scarce. For many, this journey is compounded by a near-total absence of accessible, condition-specific educational resources, leaving patients, caregivers, and families without the guidance and understanding they need at the most critical moments of their care.
The MOGAD Initiative for Navigation and Direction (MIND) was founded to bridge the gap between complex medical terminology and accessible information. MIND’s digital platform, mogad.net, has a mission to provide free, accurate, and comprehensible educational resources specifically designed for MOGAD patients, caregivers, and newly diagnosed individuals worldwide, reducing the information burden that so often accompanies a rare disease diagnosis.
A defining feature of the platform is the 3-dimensional disease mechanism simulation. When navigating through the website, patients can utilize and interact with the model in order to understand how MOGAD can affect the nervous system and how the antibodies attack the oligodendrocytes that cover the myelin sheath. Through a visual representation, the mechanism aids in comprehensibility and the foundational understanding of MOGAD. Furthermore, the platform utilizes an AI-powered pipeline that allows patients and families to navigate through the most recent clinical papers and research studies relating to MOGAD. The system saves individuals countless hours on the web, accelerating the process of understanding. Not only that, but MIND also embodies a database that allows patients to locate the nearest neuro-ophthalmologist in their immediate vicinity through the North American Neuro-Opthalmology Society (NANOS) directory.
Since launch, MIND has reached over 4,000 people in over 70 countries spanning 6 continents. The platform has additionally gained over 7,000 web views, generating over 40,000 web requests. Moreover, the organization has received positive feedback from universities and doctors from around the world, being granted partnerships along the way to advocate for patients on even larger scales. MIND has been recognized as a Community Partner by the Siegal Rare Neuroimmune Association (SRNA), The Sumaira Foundation, The Multiple Sclerosis Society of Nepal, and The Chicago MS Alliance. We have also been granted a membership to be a part of the National Organization for Rare Disorders (NORD).
MIND has a mission to facilitate patient understanding. From Ecuador to Uzbekistan, patients are in need of accessible resources that can aid them during their medical journey. With MOGAD still being researched and information being new, we are driven to help individuals navigate through uncertainty as they receive a diagnosis they might know nothing about, because for patients, understanding MOGAD starts here.
